Vineti CEO and leadership

Amy focuses on healthcare new business creation for GE Ventures/healthymagination. In addition to venture investments, Amy is driving growth strategy for new business creation portfolio companies as well as scoping and seeding independent business opportunities. Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was the co-founder and Executive Director of Proposition 71,California's $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Earlier in her career, Amy was an early employee at E-Loan, Inc., the first online consumer mortgage company, with that company through its IPO. She also worked for the World Bank Group to scale and deliver leapfrog technologies to developing economies. Amy holds an MBA and MA/BA in English from Stanford University. She was also a Coro Fellow and an Aspen Institute Socrates Fellow.

Louise brings almost 25 years of global experience in biopharmaceutical and healthcare technology to Vineti. Before joining the company as Chief Strategy Officer, she led major biopharmaceutical engagements in Europe and the U.K. for IQVIA, a global leader in the use of data, technology, and analytics to advance healthcare. She has also led large-scale technology transformation programs for global pharmaceutical leader GSK in the Asia-Pacific region and leading medical testing provider Quest Diagnostics in the United States. Earlier in her career, she managed network administration for biotech start-up CombinatorRx, where the team built a high-throughput IT platform to identify and develop new medications based on synergistic combinations of approved drugs. She holds a data science certificate in object-oriented programming from Harvard University and received her undergraduate degree from the University of North Carolina at Chapel Hill.

Amy focuses on healthcare new business creation for GE Ventures/healthymagination. In addition to venture investments, Amy is driving growth strategy for new business creation portfolio companies as well as scoping and seeding independent business opportunities. Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was the co-founder and Executive Director of Proposition 71,California's $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Earlier in her career, Amy was an early employee at E-Loan, Inc., the first online consumer mortgage company, with that company through its IPO. She also worked for the World Bank Group to scale and deliver leapfrog technologies to developing economies. Amy holds an MBA and MA/BA in English from Stanford University. She was also a Coro Fellow and an Aspen Institute Socrates Fellow.

Amy focuses on healthcare new business creation for GE Ventures/healthymagination. In addition to venture investments, Amy is driving growth strategy for new business creation portfolio companies as well as scoping and seeding independent business opportunities. Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was the co-founder and Executive Director of Proposition 71,California's $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Earlier in her career, Amy was an early employee at E-Loan, Inc., the first online consumer mortgage company, with that company through its IPO. She also worked for the World Bank Group to scale and deliver leapfrog technologies to developing economies. Amy holds an MBA and MA/BA in English from Stanford University. She was also a Coro Fellow and an Aspen Institute Socrates Fellow.